Inspire Medical Q3 revenue beats expectations, raises full-year EPS guidance

Inspire Medical Systems

03/11/2025 21:11

Overview

Inspire Medical Q3 revenue rises 10% yr/yr, beating analyst expectations

Company completed $50 mln share repurchase, indicating confidence in future growth

Transition to Inspire V system progressing well with positive clinician feedback

Outlook

Company reaffirms full-year revenue guidance of $900 mln to $910 mln

Company raises full-year diluted net income per share guidance to $0.90-$1.00

Company maintains full-year gross margin guidance at 84% to 86%

Result Drivers

INSPIRE V SYSTEM - Transition to Inspire V system contributed to revenue growth and improved gross margin due to lower cost of goods sold

POSITIVE CLINICIAN FEEDBACK - Inspire V system received positive feedback from clinicians, with 100% successful device implants and reduced surgical times

INCREASED OPERATING EXPENSES - Operating expenses rose due to patient marketing and corporate costs, partially offset by reduced R&D

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$224.5 mln
$220.46 mln (18 Analysts)
Q3 Net Income
$9.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inspire Medical Systems Inc is $125.00, about 42.3% above its October 31 closing price of $72.08

The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release: ID:nGNX1c66Cq

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)